Melanoma KOL Interview – US
Melanoma KOL Interview – US
$599.00
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Contego, PDR001, tilsotolimod, bempegaldesleukin, Lenvima, and TAVO.
Publisher: Biomedtracker
- Highlights
- Description
Highlights
Because we are an NCCN institution, I would say we follow those guidelines as close as we can with an 85:15 or 90:10 percent rule, where 85–90% of the patients are going to follow the textbook, right? They’re going to be on guidelines, they’re going to be on pathways, and then 10–20% or so are going to be offpathway. So it doesn’t always hold true to the pathways. We might have to think outside the box.
Well it’s a case by case. No two patients follow the same pathway so it’s really dependent on the patient, the patient characteristics, the tumor characteristics, the molecular characteristics. So it’s tough.
Overview
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Contego, PDR001, tilsotolimod, bempegaldesleukin, Lenvima, and TAVO.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Melanoma Disease Coverage Forecast and Market Analysis 
Sign up to the